Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of May 2019, specifically dated May 5, 2019. The filing reports the presentation of interim clinical data from the Company's Phase 1 clinical trial for its lead drug candidate, PBT434, at the American Academy of Neurology (AAN) Annual Meeting. PBT434 is an oral small molecule designed to inhibit alpha-synuclein aggregation for the treatment of synucleinopathies, including Parkinson's Disease and Multiple System Atrophy (MSA).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial progress and scientific data.
Material Changes and Clinical Results
The primary material update is the release of interim data from the Phase 1 "First in Human" study of PBT434. Key findings include:
- Safety and Tolerability: PBT434 was well tolerated in healthy adult and older adult volunteers. Adverse event (AE) rates were comparable to placebo. No serious adverse events were reported, and no subjects discontinued dosing due to adverse events.
- Pharmacokinetics: The drug demonstrated dose-dependent systemic exposure following oral administration. Mean elimination half-life was up to 9.3 hours.
- Brain Penetration: Results confirmed that PBT434 crosses the blood-brain barrier in humans. At doses of 200 mg to 250 mg twice daily (BID), cerebrospinal fluid (CSF) concentrations exceeded those associated with efficacy in animal models of MSA.
- Study Status: The study is expected to complete in mid-2019. Data presented covered initial single-dose and multiple-dose cohorts.
Outlook, Management Commentary, and Risks
Management, represented by Dr. David Stamler (Chief Medical Officer), expressed encouragement regarding the results, noting that PBT434 achieves potentially clinically relevant concentrations in the human brain at well-tolerated doses. The Company anticipates providing final data at a medical conference later in 2019.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include potential delays in financing, development, testing, and regulatory approval; unexpected adverse side effects; inadequate therapeutic efficacy; and uncertainties regarding patent protection for intellectual property.
Investor Verification Checklist
- Verify the final completion date and full dataset release for the Phase 1 trial of PBT434.
- Confirm the timeline and design for subsequent Phase 2 clinical trials in patient populations.
- Review the Company's most recent Form 20-F for current cash runway and liquidity status, as this filing contains no financial figures.
- Monitor regulatory communications regarding the orphan drug status for Multiple System Atrophy (MSA).
- Assess the status of intellectual property protection for PBT434 and the alpha-synuclein aggregation mechanism.